• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Embecta Corp.

    1/22/26 7:20:54 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care
    Get the next $EMBC alert in real time by email
    DEFA14A 1 ss5855588_defa14a.htm SCHEDULE 14A

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities
    Exchange Act of 1934 (Amendment No.)

    Filed by the Registrant ☑

    Filed by a Party other than the Registrant  ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    þ Definitive Additional Materials
    ☐ Soliciting Material Pursuant to §240.14a-12

     

    Embecta Corp.

    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    þ No fee required
    ☐ Fee paid previously with preliminary materials
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

     

     

     

     

     
     

    SUPPLEMENT TO PROXY STATEMENT DATED DECEMBER 18, 2025

    FOR THE ANNUAL MEETING OF STOCKHOLDERS

    TO BE HELD ON FEBRUARY 11, 2026

     

    Embecta Corp.
    300 Kimball Drive, Ste 300
    Parsippany, New Jersey 07054
    www.embecta.com

    Dear fellow stockholders,

    The additional materials provided herein supplement, and should be read in conjunction with, the information regarding Proposal 4 - Approval of an Amendment to the Embecta 2022 Employee and Director Equity-Based Compensation Plan contained in the definitive proxy statement (the “Proxy Statement”) of Embecta Corp. (“we,” “us,” “our” or the “Company”) filed with the Securities and Exchange Commission on December 18, 2025, regarding the annual meeting of stockholders to be held on February 11, 2026, at 8:00 a.m. EST (the “2026 Annual Meeting”). From and after the date of this supplement, any references to the Proxy Statement will be deemed to include the Proxy Statement as supplemented hereby. Capitalized terms used herein, unless otherwise defined, have the meanings set forth in the Proxy Statement.

    As more specifically described in the Proxy Statement, we are seeking stockholder approval to amend the Embecta 2022 Employee and Director Equity-Based Compensation Plan (as amended from time-to-time, the “2022 Plan”), in order to increase the number of shares available for issuance under the 2022 Plan by 2,430,000 shares (the “2022 Plan Amendment”). The 2022 Plan Amendment was approved by the Board on December 2, 2025.

    On January 19, 2026, Institutional Shareholder Services (“ISS”) issued its Proxy Analysis & Benchmark Policy Voting Recommendations (the “ISS Report”) related to the 2026 Annual Meeting. In the ISS Report, ISS recommended that stockholders vote against the proposal to approve the 2022 Plan Amendment. The commentary below addresses certain key concerns outlined in the ISS Report and provides supplemental data to ensure our stockholders have an opportunity to vote their shares on the basis of accurate, up-to-date information.

    The 2022 Plan cost is reasonable.

    Among the reasons provided by ISS for its negative voting recommendation was the determination by ISS that the stockholder value transfer, or SVT, exceeded applicable ISS SVT benchmarks. ISS had assumed a calculation date for purposes of analyzing SVT as of September 30, 2025. We had specifically calculated our share request as of November 30, 2025. Correcting these assumptions, we believe, will bring our plan within the parameters of ISS guidelines.

    Share Activity as of November 30, 2025(1)

    Number of Common Shares Outstanding 59,211,232
    Number of Shares Attributable to the GSIP 642,942
    Number of Outstanding SARs 1,427,452
    Weighted Average Exercise Price 29.37
    Weighted Average Remaining Contractual Term (Years) 5.69
    Number of Outstanding TVUs 2,972,427
    Number of Outstanding PSUs(2) 1,722,979
    Share Reserve under 2022 Plan 791,505
    (1)All data in the table, with the exception of the Number of Shares Attributable to the GSIP, is based upon awards issued under the 2022 Plan and does not otherwise include awards issued under any other plan. No other plans have awards outstanding or shares available for future awards.

     

     

     
     

     

    (2)The Company has determined that the service inception date precedes the grant date for certain PSU awards as (a) the awards were authorized prior to establishing an accounting grant date, (b) the recipients began providing services prior to the grant date, and (c) there are performance conditions that, if not met by the accounting grant date, will result in the forfeiture of the awards. The number shown here represents the full number of outstanding PSUs as of November 30, 2025, inclusive of 952,203 awards which contain targets that will be fully established at a future date.

    The Board reiterates its recommendation that you vote “FOR” the approval of Proposal 4.

    If you have already voted, you do not need to vote again unless you would like to change or revoke your prior vote on any proposal. If you would like to change or revoke your prior vote on any proposal, please refer to page 80 of the Proxy Statement for instructions on how to do so.

     

    Sincerely,

     

    Jeff Mann

    Senior Vice President, General Counsel and Product Development

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $EMBC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EMBC

    DatePrice TargetRatingAnalyst
    4/10/2025$15.00Neutral
    Mizuho
    12/2/2024$13.00 → $20.00Underweight → Equal-Weight
    Morgan Stanley
    11/27/2024$26.00Neutral → Buy
    BTIG Research
    10/20/2023Peer Perform
    Wolfe Research
    1/6/2023$28.00Equal-Weight → Underweight
    Morgan Stanley
    9/8/2022Neutral
    BTIG Research
    8/1/2022$33.00Equal-Weight
    Morgan Stanley
    6/21/2022$25.00Underperform
    BofA Securities
    More analyst ratings

    $EMBC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    5/23/25 4:35:56 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    2/25/25 4:26:16 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Melcher David F bought $32,500 worth of shares (2,000 units at $16.25), increasing direct ownership by 5% to 45,080 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    2/12/24 7:08:59 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by SVP, GC, Head Corp. Dev., Secy Mann Jeffrey Z

    4/A - Embecta Corp. (0001872789) (Issuer)

    12/3/25 4:48:42 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 4 filed by SVP and CFO Elguicze Jacob

    4/A - Embecta Corp. (0001872789) (Issuer)

    12/3/25 4:45:38 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Chief Accounting Officer Roth Anthony M. was granted 32,817 shares and covered exercise/tax liability with 1,881 shares, increasing direct ownership by 188% to 47,415 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    12/1/25 9:31:37 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Embecta Corp. with a new price target

    Mizuho initiated coverage of Embecta Corp. with a rating of Neutral and set a new price target of $15.00

    4/10/25 12:41:09 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Embecta Corp. from Underweight to Equal-Weight and set a new price target of $20.00 from $13.00 previously

    12/2/24 6:56:10 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. upgraded by BTIG Research with a new price target

    BTIG Research upgraded Embecta Corp. from Neutral to Buy and set a new price target of $26.00

    11/27/24 7:22:14 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.

    SCHEDULE 13G/A - Embecta Corp. (0001872789) (Subject)

    1/30/26 1:27:57 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Embecta Corp.

    DEFA14A - Embecta Corp. (0001872789) (Filer)

    1/22/26 7:20:54 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Embecta Corp.

    DEFA14A - Embecta Corp. (0001872789) (Filer)

    12/18/25 4:17:49 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    embecta to Report Fiscal First Quarter Financial Results

    PARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal first quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 5, 2026. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11

    1/22/26 5:00:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta to Participate at the J.P. Morgan 2026 Healthcare Conference

    PARSIPPANY, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (NASDAQ:EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 2:15 p.m. PT / 5:15 p.m. ET. Audio webcasts of the presentations will be accessible under the "News & Events" section of the Company's investor relations website at investors.embecta.com. About embectaembecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the glo

    12/18/25 5:00:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2026 Financial Guidance

    PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2025. "Our fourth quarter results were largely in line with our expectations, with revenue lower year over year due to several items we had previously anticipated, including the impact of advanced distributor ordering in the fourth quarter of fiscal year 2024 in advance of a potential U.S. port strike; the impact of advanced distributor ordering in the third quarter of fiscal year 2025 in advance of the U.S. July 4th holiday; and the continuing business dyna

    11/25/25 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Financials

    Live finance-specific insights

    View All

    embecta to Report Fiscal First Quarter Financial Results

    PARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal first quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 5, 2026. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11

    1/22/26 5:00:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2026 Financial Guidance

    PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2025. "Our fourth quarter results were largely in line with our expectations, with revenue lower year over year due to several items we had previously anticipated, including the impact of advanced distributor ordering in the fourth quarter of fiscal year 2024 in advance of a potential U.S. port strike; the impact of advanced distributor ordering in the third quarter of fiscal year 2025 in advance of the U.S. July 4th holiday; and the continuing business dyna

    11/25/25 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta Announces Quarterly Cash Dividend

    PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 18, 2025 to stockholders of record at the close of business on December 5, 2025. About embectaembecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social

    11/25/25 6:00:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Leadership Updates

    Live Leadership Updates

    View All

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

    3/11/25 7:00:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors

    WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world.  "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the

    6/20/24 7:30:00 AM ET
    $EMBC
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    $EMBC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Embecta Corp.

    SC 13G/A - Embecta Corp. (0001872789) (Subject)

    11/8/24 10:57:43 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Embecta Corp.

    SC 13G/A - Embecta Corp. (0001872789) (Subject)

    11/7/24 4:21:15 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Embecta Corp.

    SC 13G - Embecta Corp. (0001872789) (Subject)

    10/25/24 5:45:30 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care